SGSimon Gollins

Simon Gollins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simon Gollins has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • S. Myint

    4 shared publications
  • S. Susnerwala

    3 shared publications
  • A. Biswas

    North Wales Cancer Treatment Ctr, Denbighshire, United Kingdom; Clatterbridge Ctr for Oncology, Liverpool, United Kingdom; Christie Hosp, Manchester, United Kingdom; Royal Preston Hosp, Preston, United Kingdom

    2 shared publications
  • B. Haylock

    North Wales Cancer Treatment Ctr, Denbighshire, United Kingdom; Clatterbridge Ctr for Oncology, Liverpool, United Kingdom; Christie Hosp, Manchester, United Kingdom; Royal Preston Hosp, Preston, United Kingdom

    2 shared publications
  • E. L. Levine

    2 shared publications
  • M. Saunders

    North Wales Cancer Treatment Ctr, Denbighshire, United Kingdom; Clatterbridge Ctr for Oncology, Liverpool, United Kingdom; Christie Hosp, Manchester, United Kingdom; Royal Preston Hosp, Preston, United Kingdom

    2 shared publications

Latest Publications

  • Biomodulation of irinotecan using ciclosporin: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).

    by G. W. Middleton, S. J. Gwyther, S. R. Brown, T. Maughan, C. Olivier, S. Richman, N. R. Maisey, M. Hill, S. Gollins, S. Myint, et al.

    3566 Background: Phase I/II data showed that ciclosporin (Cs) profoundly reduces the hepatobiliary clearance of irinotecan (Ir), and suggested that 40% standard dose Ir with concurrent Cs (IrCs) may give equal efficacy to standard Ir, with less diarrhoea. PICCOLO is a multicentre randomized controlled trial in which patients (pts) with aCRC, progressing after prior therapy, were randomised to Ir or IrCs. It was designed to detect non-inferior efficacy with reduced toxicity. Methods: Eligible pts had: measurable aCRC, progressive during/after ≥1 prior regimen with fluoropyrimidines ± other drugs; no prior Ir; WHO PS 0-2. Before summer 2008, pts were allocated 1:1:1 (without prospective KRAS analysis) to Ir, IrCs or Ir/panitumumab. Thereafter, KRAS was analysed prospectively and pts with mutated or undetermined KRAS were allocated 1:1 to Ir (irinotecan 350 mg/m2 [300 mg/m2 if ≥70 yrs or PS2], q3w), or IrCs (irinotecan 140 mg/m2 [120 mg/m2 if ≥70 yrs or PS2] d1, Cs 3 mg/kg tds d0-2, q3w). The primary efficacy endpoint was % pts alive and progression-free at 12 wks, with a lower non-inferiority boundary of -10.6% (80% power, 2.5% significance). Grade ≥3 diarrhoea within 12 wks was a key secondary endpoint. PFS, OS, RR, QoL and loperamide use were also assessed. Analysis was performed on both the ITT and per-protocol populations. Results: 672 pts were randomised between Ir and IrCs. Median age was 64 yrs; 92% were PS0/1; 95% had received prior oxaliplatin; KRAS was mut in 60%, wt in 25%, unknown in 15%. ITT analysis showed 179/335 (53.4%) patients to be progression-free at 12 wks in the Ir arm, 159/337 (47.2%) in the IrCs arm. The difference was therefore -6.3% and the 95% CI crossed the prespecified non-inferiority margin (13.8%, +1.3%). Gr ≥3 diarrhoea was uncommon in both arms (Ir 12.2%; IrCs 10.1% pts), but fewer IrCs patients took loperamide within 12 wks (Ir 67.8%; IrCs 52.2%, p<0.001). Conclusions: As anticipated, IrCs was associated with less diarrhoea as assessed by loperamide use, but severe diarrhoea was uncommon in both arms. However, we failed to prove non-inferiority of IrCs compared with Ir, so cannot recommend it as a standard treatment option based on these data.

  • Preoperative chemoradiation (CRT) with concurrent capecitabine and irinotecan in MRI-defined locally advanced rectal cancer: Relationship of histologic downstaging to long-term survival end points.

    by S. W. Gollins, S. Myint, S. Susnerwala, M. Wise, B. J. Haylock, M. P. Saunders, R. Neupane, C. Topham, L. M. Samuel, E. L. Levine

    3636 Background: There is a need to increase the efficacy of preoperative downstaging CRT in locally advanced rectal cancer. Methods: Patients (median age 62 ), with rectal adenocarcinoma without distant metastases, entered this phase I/II trial (NWCOG-2) following MRI demonstration of threatened (≤ 2 mm) or involved mesorectal fascia. Pelvic radiotherapy (RT) was given to 45 Gy in 25 daily fractions in 5 weeks with concurrent oral capecitabine continuously days 1-35 at 650 mg/m2 bd (n = 110) or 825 mg/m2 bd (n = 25) and IV irinotecan once weekly in weeks 1-4 of RT at 50 mg/m2 (n = 3), 60 mg/m2 (n = 127) or 70 mg/m2 (n = 5). Patients later underwent surgical resection with total mesorectal excision (TME). Results: Between Sept 03 and Dec 06 142 patients commenced CRT with 135 patients undergoing TME a median of 61 days post-CRT. Pretreatment MRI stage of the 135 resected patients was T2: 2 (1%), T3: 100 (74%), T4: 33 (24%), N0: 31 (23%), N1: 67 (50%) and N2: 37 (27%). Histology post resection showed downstaging for T stage in 82 (61%) patients and for N stage in 83 (80%) of 104 initial N1-2 patients. 31 patients (23%) were T0 and 123 (91%) had a negative circumferential resection margin (CRM). With median follow-up of 33 months 3 patients (2%) had a local pelvic recurrence only, 33 (24%) distant metastases only and 2 (1%) both pelvic and distant. The 3-year local recurrence-free survival (LRFS) was 97.1%, metastasis-free survival (MFS) 71.4%, disease-free survival (DFS) 63.5% and overall survival (OS) 82.8%. By univariate analysis greater histologic T stage (T0 vs. T1-2 vs. T3-4) and N stage (N0 vs. N1-2) downstaging was significantly associated with superior MFS, DFS and OS. Initial MRI T and N stage, CRM status, gender, age, operation type (anterior resection vs. AP resection) and adjuvant chemotherapy (yes vs. no) were not. However, on Cox multivariate analysis only histologic T stage remained significant for MFS (p = 0.004), DFS (p = 0.005) and OS (p = 0.005). Conclusions: In poor-risk rectal cancer this CRT regimen shows high response rates and promising long-term survival. T stage downstaging may be a useful surrogate for long-term survival.


  • Open Access

    Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2)

    by S W Gollins, S Myint, S Susnerwala, B Haylock, M Wise, C Topham, L Samuel, R Swindell, J Morris, L Mason, et al.

    Background: Methods: Results: Conclusion:


  • Open Access

    Tongue metastasis as an initial presentation of renal cell carcinoma: a case report and literature review

    by Faisal Azam, Muneer Abubakerr, Simon Gollins

    Primary tumour of the kidney metastasizing to the tongue is very unusual and only anecdotal cases have been reported. An exhaustive literature review covering the period from 1911 onwards disclosed 28 cases. Out of those, only 3 cases presented initially with tongue metastases before the diagnosis of primary renal cell carcinoma.


  • RCT on gentian violet versus a hydrogel dressing for radiotherapy-induced moist skin desquamation

    by S. Gollins, C. Gaffney, S. Slade, R. Swindell

    Objective: Radiotherapy-induced moist desquamation is a significant problem but there is a paucity of randomised data on which to base treatment decisions. The current prospective randomised trial compared gentian violet (GV) to a hydrogel dressing in this context. Method: Thirty patients undergoing radiotherapy to the head and neck region or breast who had developed moist desquamation in the radiotherapy field were randomised to treatment with 0.5% aqueous gentian violet (GV) (n=16) or a hydrogel dressing (n=14). The area of desquamation was regularly measured until healing or withdrawal from the study. Results: The likelihood of healing with the hydrogel was greater than GV with a hazard ratio for healing of 7.95 (95% CI 2.20–28.68; p=0.002). The median time to healing for hydrogel was 12 days but had not been reached for GV by 30 days. Over the first 14 days the median ‘area under curve’ of moist desquamation for GV was 82.6 cm2 (range 31.8–320.7cm2) and that for hydrogel 20.0 cm2 (range 3.8–301.0cm2) (difference significant at p=0.003). Ten of 16 patients treated with GV withdrew from the study (due to stinging in five and failure to heal in five) compared with two of the 14 treated with hydrogel (difference significant at p=0.021). Conclusion: Hydrogel dressings are more likely to heal radiotherapy-induced moist desquamation and are better tolerated than GV. Declaration of interest: None.


  • Phase I study of radiotherapy (RT) plus concurrent irinotecan (CPT-11) and capecitabine (CAP) as preoperative downstaging treatment for locally advanced inoperable rectal cancer

    by S. W. Gollins, S. Myint, E. Levine, J. Morris, B. Haylock, S. Susnerwala, M. Saunders, A. Biswas

    3565 Background: Preoperative downstaging chemoradiation has become standard treatment for locally advanced unresectable rectal cancer. Oral CAP is potentially more convenient as a radiation sensitiser than infusional fluoropyrimidine regimes. This study evaluated the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended dose (RD) of daily CAP plus weekly i.v. CPT-11 when used in combination with RT in locally advanced rectal cancer. Methods: Patients had an adenocarcinoma of the rectum that was considered to be inoperable because of involvement of the surgical excision plane on MRI scanning. On MRI, tumours were either T3 within 2 mm of the mesorectal outer edge, T4, or any T3 within 5 cm of the anal verge. There were no distant metastases on staging investigations. Patients received planned pelvic RT to 45 Gy in 25 daily fractions over five weeks, concurrent with oral CAP daily throughout RT (including weekends) and a 60 minute infusion of i.v. CPT-11 during weeks 1, 2, 3 and 4 of RT. Doses of CAP and CPT-11 were gradually escalated in cohorts of three patients. Results: There was no grade 4 toxicity. The most common DLT was diarrhoea. Two of six patients encountered DLT at dose level 4 (one grade 3 diarrhoea and one grade 3 neutropenic infection-see table below). The RD chosen was dose level 3. 20 patients were eligible for resection at the time of writing: 3 could not be resected (1 developed liver metastases and 2 deteriorated post chemoradiation) and 17 patients were resected (16 histologically R0 and one R1). 4 patients had a complete pathological response (PCR) and 4 a ‘near’ PCR. Conclusions: The RD for this regime is 60 mg/m2 i.v. CPT-11 weeks 1, 2, 3, 4 and 825 mg/m2 bd of oral CAP daily including weekends, concurrent with RT. This is tolerable and demonstrates promising early signs of efficacy. The RD is currently being studied in an expanded phase II cohort of 50 patients. No significant financial relationships to disclose.


  • Phase II study of radiotherapy plus concurrent irinotecan (CPT-11) and infusional 5-fluorouracil (5FU) in the treatment of T3-T4 locally advanced inoperable rectal cancer

    by E. L. Levine, S. Gollins, S. Susnerwala, B. Haylock, M. Saunders, S. Myint, A. Biswas

    3612 Background: Previously, we reported a Phase I study of radiotherapy with concurrent CPT-11 and 5FU for the treatment of locally advanced inoperable rectal cancer (Proc ASCO 2003, abst 1384). In combination with pelvic radiotherapy of 45 Gy in 25 daily fractions over five weeks, this established a recommended dose for CPT-11 of 60 mg/m2 given once per week, during weeks 1, 2, 3 and 4 as a 60 minute infusion, together with continuous infusional 5FU at 200 mg/m2 per day via a central line throughout radiotherapy, including weekends. This dose level was expanded to a cohort of thirty one patients for the present phase II assessment. Methods: All patients were initially staged using MRI. Patients with T3 (with threatened mesorectal edge on MRI scan) or T4 rectal cancer, were treated with the above regime. Surgery was performed 6 - 8 weeks following the completion of chemoradiation. Results: All patients completed chemoradiation as planned. There was only one grade 3 toxicity reported (diarrhoea) and the patient completed treatment successfully. Thirty-one patients entered, of whom twenty-nine (93%) underwent resection. Two patients were deemed inoperable because of unresectable pelvic disease. Sixteen patients (55%) had an anterior resection and thirteen patients (45%) had an abdomino-perineal resection. Twenty-six patients (87%) had complete excision of the tumour (Ro resection). Six patients (21%) had a complete response to chemoradiation (pCR). Four patients in addition (14%) had microfoci only of tumour remaining (near-pCR). Conclusions: Radiotherapy with concurrent CPT-11 and 5FU is a well tolerated treatment for locally advanced inoperable rectal cancer leading to a high probability of complete resection of the cancer. This treatment regime is currently being studied (in the NWCOG-2 trial), in a similar cohort of rectal cancer patients, but substituting Capecitabine for 5FU.